<DOC>
	<DOCNO>NCT00052442</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness 10-propargyl-10-deazaaminopterin treating patient recurrent refractory non-Hodgkin 's lymphoma Hodgkin 's lymphoma .</brief_summary>
	<brief_title>10-Propargyl-10-Deazaaminopterin Treating Patients With Recurrent Refractory Non-Hodgkin 's Lymphoma Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy 10-propargyl-10-deazaaminopterin , term objective response rate , duration response , time disease progression , patient relapse refractory aggressive non-Hodgkin 's lymphoma Hodgkin 's lymphoma . - Determine impact pharmacokinetics toxicity drug elimination patient treat drug . - Determine toxicity drug patient . - Determine effect prior chemotherapy response duration duration response patient treated drug . - Correlate , possible , pharmacodynamics ( area curve ) drug tumor response toxicity ( mucositis ) patient . - Correlate , possible , intraerythrocytic folate homocysteine level severity mucositis patient treat drug . - Determine whether level RFC-1 folate transporter , folylpolyglutamate synthetase , folylpolyglutamate hydrolase marker response patient treated drug . OUTLINE : This open-label study . Patients receive 10-propargyl-10-deazaaminopterin IV 1 hour day 1 . Courses repeat every 14 day absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) may receive 2 additional course beyond CR . PROJECTED ACCRUAL : A total 39-72 patient ( 12-35 cohort 1 17-37 cohort 2 ) accrue study within 10-36 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Aminopterin</mesh_term>
	<mesh_term>10-deazaaminopterin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Hodgkin 's lymphoma , use WHO classification , aggressive nonHodgkin 's lymphoma include : Large B Tcell lymphoma ( include transform lymphoma ) Mantle cell lymphoma Immunoblastic lymphoma At least 1 unidimensionally measurable lesion At least 2 cm conventional technique OR At least 1 cm spiral CT scan Lymph node great 1 cm short axis consider normal Relapsed refractory disease firstline chemotherapy Cohort 1 : No 3 prior conventional cytotoxic chemotherapy regimens Must least partial response ( PR ) last 6 month refractory disease Patients disease refractory relapse less 100 day peripheral blood stem cell ( PBSC ) transplantation eligible Cohort 2 : No limit prior treatment Must least PR last therapy last least 6 month Patients receive highdose chemotherapy part PBSC transplantation eligible relapse occur least 100 day transplantation No clinically significant pleural effusion ascites No active brain leptomeningeal metastasis Treated CNS disease allow PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count great 1,000/mm^3 Platelet count great 75,000/mm^3 Hemoglobin least 10 g/dL Hepatic Bilirubin less 1.5 time upper limit normal ( ULN ) AST/ALT great 2.5 time ULN ( 4 time ULN liver involvement ) Alkaline phosphatase great 5 time ULN Renal Creatinine great 1.5 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular No symptomatic congestive heart failure No New York Heart Association class III IV heart disease No unstable angina pectoris No cardiac arrhythmia No myocardial infarction , cerebrovascular accident , transient ischemic attack within past 6 month No history orthostatic hypotension No EKG evidence acute ischemia significant conduction abnormality ( e.g. , bifascicular block 2nd 3rd degree atrioventricular block ) No uncontrolled hypertension require active manipulation antihypertensive medication No grade III IV edema Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No ongoing active infection Febrile episodes 38.5Â° Celsius without sign active infection allow No concurrent active cancer No concurrent serious medical illness No psychiatric illness social situation would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics At least 3 month since prior monoclonal antibody therapy ( e.g. , rituximab ) Chemotherapy See Disease Characterisitics At least 4 week since prior cytotoxic chemotherapy ( 6 week mitomycin nitrosoureas ) recover Endocrine therapy At least 7 day since prior steroid No concurrent steroid Radiotherapy See Disease Characteristics At least 4 week since prior radiotherapy recover Surgery More 4 week since prior major surgery Other No prior antifolates No concurrent folic acid supplementation No concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational commercial agent therapy intent treat malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
</DOC>